Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

Shanghai, China, January 8, 2026 — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women’s health, announces that the first patient in China has been enrolled in the Phase I clinical trial of its self-developed APL-2401 (ASN-8639 tablets) for patients with FGFR2/3-driven advanced solid tumors. APL-2401 is a […] The post Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors appeared first on Asieris Pharmaceuticals .